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AML-induction chemotherapy related HUS
Hemolytic uremic syndrome (HUS) as a rare
complication of induction chemotherapy for acute
myeloid leukemia (AML) without maturation
CASE REPORT
  A 75-year-old male was admitted to the 
hospital in November 2002 with high-grade 
fever (above 38℃), cough, hypoxia, and 
progressive  general  lassitude.  Laboratory 
findings showed the folowing: hemoglobin 
level, 5.9 g/dl; leukocytes, 31,890/μl with 
79.5% blast; platelet count, 26,000/μl; and 
reticulocytes, 0.877%. There were no morpho-
logical abnormalities of the red blood cels at 
that time. Other significant laboratory findings 
included serum lactic dehydrogenase (LDH) 
1,107 IU/l; blood urea nitrogen (BUN), 35 
mg/dl; creatinine, 1.6 mg/dl; and C-reactive 
protein, 6.2 mg/dl. A bone marrow aspiration 
was performed. His bone marrow yielded over 
90% of blast without diferentiation and with 
myeloperoxidase and surface marker folowing 
CD13, CD33 and HLA-DR were positive. He 
was diagnosed with acute myeloid leukemia 
without maturation.
　He received one cycle of remission-induction 
therapy with 25 mg/m2 daunorubicin (DNR) on 
days 1-3 and 200 mg/m2 behenoyl-ara-C 
(BHAC) on days 1-7. Sulfamethoxazole/ 
trimethoprim (ST), ciprofloxacin hydrochloride 
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　A 75-year-old male was diagnosed with acute myeloid leukemia without maturation 
and was treated with combination chemotherapy. After the first remission-induction 
therapy, he reached complete remission. About one month after the first induction 
therapy, he was diagnosed with a complication of chemotherapy-related HUS (C-HUS). 
He gradualy recovered from the C-HUS after the initiation of a plasma exchange. 
　In conclusion, it seems that the anti-leukemic drugs might play an important role in 
the development of chemotherapy C-HUS.
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(CFPX), and itraconazole (ITCZ) were adminis-
tered for prophylaxis of an opportunistic 
infection from day 1. On day 30 after the first 
chemotherapy, his bone marrow achieved 
complete remission, and his hemopoiesis 
slowly recovered. 
　In the middle of December, hypertension and 
oliguric started to be gradualy noted, although 
there were no remarkable respiratory symp-
toms, including sore throat, cough, dyspnea, or 
abdominal symptoms such as nausea, vomit-
ing, and diarrhea. Urinalysis presented 
hematuria and mild proteinuria. Anemia and 
thrombocytopenia then progressed. Although 
fragmented erythrocytes and schistocytes were 
noted on the peripheral blood smear, there 
were  no  morphological  abnormalities  of 
leukocytes. Direct and indirect Coombs tests 
were negative. Acute renal failure was very 
severe, with disturbing values of 118 mg/dl 
BUN  and  7.20  mg/dl  creatinine.  Other 
significant laboratory values included serum 
1,996 IU/l LDH and 6.3 mg/dl C-reactive 
protein, but the unconjugated bilirubin was 
almost normal. The prothrombin time and 
activated prothrombin time were both normal, 
although fibrinogen was slightly increased 
(400 mg/dl) with normal fibrin degradation 
products. In spite of the fact that there was no 
evidence of disseminated intravascular coagula-
tion (DIC), Thrombomodulin (TM), which is 
associated with endothelial cel damage and 
the activation of the von Wilebrand factor, 
increased remarkably, as shown in Table 1. As 
oliguria developed into anuria, the patient 
demonstrated moderate irritability and drowsi-
ness. We thought that these findings indicated 
thrombotic microangiopathy (TMA), such as 
hemolytic hemolytic uremic syndrome (HUS) 
and thrombotic thrombocytopenic purpura 
(TTP). Continuous hemodialysis and plasma 
exchange were started; simultaneously, we 
investigated von Wilebrand factor cleaving 
protease activation (vWF-CP), which was lost 
in TTP.  In addition, his blood culture was 
negative and stool culture grew E.coli, which 
was not the O157 strain and was negative for 
verotoxin. However, his vWF-CP activation 
remained at 52%. Therefore, chemotherapy-
related HUS was diagnosed.
　After 12 days of hemodialysis and plasma 
exchange, the BUN, creatinine, LDH, and TM 
　Table 1. Summary of laboratory data
Feb.21Feb.10Jan.15Jan.05,03Dec.17NOv.05,02
6,770/04,290/01,250/01,300/06,010/031,890/79.5WBC (/μl)/blast (%)
6.47.57.28.37.25.9Hb (g/dl)
8.44.73.85.05.12.6Plt (x104/μl)
0.50.61.20.90.30.2T.Bil (mg/dl)
7841,2432,4101,4121,9961,397LDH (IU/l)
20/1.664/3.091/4.055/3.9118/7.235/1.6BUN/ Crea (mg/dl)
(+)/(+)(+)/(+)(+)/(+)(+)/(+)(+)/(+)(+)/(－)Proteinuria/Hematuria
(+)(+)(+)(+)(+)(－)RBC fragmentation
367478317294vWF activity (%)
13.726.524.129.526.5TM (FU/ml)
－31－
AML-induction chemotherapy related HUS
levels decreased, and the patient experienced 
renal  failure,  although  his  neurological 
symptoms improved temporarily in the middle 
of January.
　However, the patient’s respiratory condition 
worsened gradualy in late February. We 
diagnosed pneumonia with congestive heart 
failure. Although oxygen therapy, antibiotics, 
and  diuretics  were  started  with  other 
supportive therapies, he died three months 
after admission.
DISCUSSION
　We presented a patient with HUS that 
developed after induction chemotherapy for 
AML. TMA includes HUS, and TTP is a 
common complication in patients with cancer. 
Chemotherapy-related HUS (C-HUS) has a 
tendency to occur as a complication in patients 
who have achieved a partial or complete 
response to therapy for carcinoma as gastric 
cancer and is closely associated with the usage 
of MMC and 5-FU 1). 
　However, a few cases of patients developing 
C-HUS after treatment for acute leukemia 
have been reported 2), 3). This patient main-
tained vWF-CP activation of 52% beside he had 
severe renal failure and hemolytic anemia with 
fragmented erythrocytes. We made a diagnosis 
of C-HUS according to clinical features and 
laboratory findings.
　The patient’s TM levels were very high. 
Mori et al reported that TM levels were 
significantly higher in patients of HUS who 
died than in patients who survived 4). It seems 
that TM levels may reflect the severity of C-
HUS in a patient.
　After the start of hemodialysis and plasma 
exchange, the abnormal findings due to C-HUS 
gradualy improved. Although C-HUS is rare 
at the onset, during, and after induction 
chemotherapy for acute leukemia, it can be a 
fatal complication. We emphasize that quick 
diagnoses for C-HUS are necessary so that 
therapies, such as hemodialysis or plasma 
exchange, can be started as soon as possible.
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